AS MANY AS 1 IN 10 WOMEN IS LIKELY TO HAVE AN OVARIAN CYST IN HER LIFETIME.
An ovarian cyst happens when fluid accumulates within a thin membrane inside the ovary. Ovarian cysts are frequently found incidentally in asymptomatic women, and may sometimes be found in the course of evaluating women for pelvic pain. Studies show that between 8% --18% of both premenopausal and postmenopausal women have ovarian cysts, with post-menopausal cysts persisting for years. In the United States, approximately 5-10% of women will undergo surgical investigation for ovarian cysts in their lifetime, and in 13 - 21% of these investigations, cysts will be found to to be malignant1.
There were 1,506 cases of Ovarian Cancer in Singapore, from 2007 – 2011 according to the Singapore Cancer Registry Annual Registry Report. Currently no screening method has proven effective in detecting early stage ovarian cancer. The existing biomarkers such as CA125 suffer from lack of specificity in early stage detection, and existing tissue histology can take two weeks for diagnosis.
BENEFITS OF OVACIS™ TECHNOLOGY
ADVANTAGES OVER FROZEN SECTION
Diagnosis for ovarian cancer has routinely been performed via frozen section, which is subject to technical error, leading to misdiagnosis. In comparison, OvaCis™ relies on cyst fluid which is homogenous, resulting in higher accuracy.
VALUE IN BORDERLINE CASES
Studies have shown that with frozen section, borderline tumours have been found to have the lowest sensitivity of 31.2%, of the mucinous category, compared to Ovacis™, which accurately discriminates between benign & malignant ovarian cysts.
HIGH NEGATIVE PREDICTIVE VALUE
Ovacis™ has a Negative Predictive Value of over 98% so clinicians can be confident of providing results for benign ovarian cysts.
COST EFFICIENT AND CONVENIENT TO USE
OvaCis™ is ideal for medical settings with no on-site facilities for histology, and costs less than frozen section. It does not require trained pathologists, substantially reduces operating theatre time, and frees up resources in the laboratory.
BETTER PATIENT PROGNOSIS
OvaCis™ reduces operating theatre time and the patient’s surgical exposure in the operating theatre. It is the first of its kind Point-Of-Care device that returns a result in about 5 minutes, improving patient’s prognosis during surgery.
1. Subbian et al. in a study involving 135 cases of ovarian tumors found an overall accuracy of 84.2 %. They found the lowest sensitivity for borderline tumors (31.2 %) especially of the mucinous category .